22 publications
Name | Date | Type | Actions |
---|---|---|---|
Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China. |
13/12/2019 | Public releases | |
Q3 2019 sales: €100.2 million (Up 11.0%) The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year. |
16/10/2019 | Public releases | |
First half 2019 results At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements. |
25/07/2019 | Public releases | |
Vetoquinol announces a new milestone in its industrial strategy Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners. |
12/07/2019 | Public releases | |
Combined ordinary and extraordinary general meeting May 21, 2019 The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin. |
22/05/2019 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2018 (french version) The registration document of Vetoquinol relative to fiscal year 2018, including the annual financial report relative to fiscal year 2018, was filed with the Autorité des marchés financiers (“the AMF”) on April 29, 2019.
|
29/04/2019 | Public releases | |
Q1 2019 sales: €90.9 million (up 3.7%) Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year. |
17/04/2019 | Public releases | |
Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.
|
16/04/2019 | Public releases | |
Vetoquinol signs agreement to acquire Clarion Biociênciasin Brazil On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás. |
04/04/2019 | Public releases | |
Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%) At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements. |
20/03/2019 | Public releases | |
2018 sales: up 3.2% to €367.9 million 9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES
|
24/01/2019 | Public releases | |
Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan. |
03/12/2015 | Public releases | |
September 2015 year-to-date sales up 8.7% to €251.8 million Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%. |
22/10/2015 | Public releases | |
VETOQUINOL launches UPCARD©, an innovative drug for congestive heart failure in dogs Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs. |
14/09/2015 | Public releases | |
First half 2015 sales €167.2m, up 11.9% The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements. |
30/07/2015 | Public releases | |
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french) Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites |
30/07/2015 | Public releases | |
Vétoquinol is eligible for new PEA-PME funds Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree |
23/05/2015 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version) The registration document of Vétoquinol relative to fiscal year 2014, including the annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 17, 2015. |
20/04/2015 | Public releases | |
Q1 2015 sales show solid growth at €81.3 million (up +11.0%) Vétoquinol posted first quarter 2015 sales of €81.3 million (after currency gains of €4.5 million), up +11.0%. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in Q1 2014. |
14/04/2015 | Public releases | |
Reference products up +13.2%. net income up +9.3% Lure, March 23, 2015 – At its meeting on March 17, 2015, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the 2014 financial statements. |
23/03/2015 | Public releases | |
Vétoquinol and Orion Pharma Animal Health enter into distribution collaboration Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products. |
05/02/2015 | Public releases | |
2014 sales up 5.2% to €315.3 million The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014. |
22/01/2015 | Public releases |